Company intelligence / Profile preview

CisThera

Kirkland, Washington, United Statescisthera.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

CisThera is developing monoclonal antibody-based therapeutics targeting cancer, autoimmune disorders, and chronic organ diseases. Its lead asset for kidney disease is in preclinical development. Another program targeting FGFRs for bone metastases was discontinued. No clinical results are available yet.

Therapeutic areas: GastroenterologyOncologyImmunologyNephrology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Drug pipeline

1 asset

PAI-1 inhibitor

Pre-clinical

Indications: Fibrosis

Partnerships

None publicly disclosed.

Beyond the preview

Go deeper on CisThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CisThera.

Explore the full profile